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1388Objective: Although stem cells hold a great therapeutic potential for injured tissues, limited survival of
transplanted stem cells has hindered the clinical application of this technology. We hypothesized that an
omentum-based stem cell–supporting patch could provide adequate nutrients and microenvironment to prolong
cell survival. We examined this hypothesis in rats with experimental myocardial infarction.
Methods: The omentum-based supporting patch was constructed by stitching polylactic acid-co-glycolic acid
polymer seeded with mesenchymal stem cells from male Sprague–Dawley rats. Eight weeks after the experimen-
tal myocardial infarction, which was created by ligating the left coronary artery of female Sprague–Dawley rats,
mesenchymal stem cells were transplanted with (n¼ 16) or without (n¼ 14) the supporting patch. After 4 weeks,
transplanted mesenchymal stem cell survival, ventricular remodeling, and cardiac performance were examined.
Results: Significantly more cells survived after 4 weeks in rats transplanted with mesenchymal stem cells on the
supporting patch assessed by means of polymerase chain reaction detection of the Sry gene than seen in those without
the supporting patch (2.61 0.40 vs 1.19 0.12,P<.05). Rats with myocardial infarction that received mesenchy-
mal stem cells with the patch also had significantly improved ventricular remodeling and cardiac function than those
without the patch. Wrapping infarcted myocardium with omentum alone did not change the myocardial function.
Conclusions: The omentum-based cell-supporting patch provided a favorable microenvironment for transplanted
mesenchymal stem cell survival, which resulted in favorable ventricular remodeling and restoration of cardiac
function in rats with experimental myocardial infarction. Further validation of the technique in human subjects
could make mesenchymal stem cell transplantation a viable therapeutic option for patients with cardiac disease.
(J Thorac Cardiovasc Surg 2010;140:1388-96)Supplemental material is available online.
Despite a continuous decrease in recent decades, myocardial
infarction (MI) remains the leading cause of mortality and
morbidity in most countries. After MI, cardiomyocytes
die, and fibrous scars form in the infarction zone. Although
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The Journal of Thoracic and Cardiovascular Surhave been successful in revascularizing the ischemic tissues,
there is thus far no effective treatment to regenerate cardio-
myocytes that have dies as a result of infarction.
Pluripotent mesenchymal stem cells (MSCs) have been
shown to potentially serve as a cell source for cardiac tissue
regeneration.1 Recently, stem cell–based treatment for MI or
heart failure has been tested in human patients worldwide.
The clinical outcome, however, was inconsistent and short
lived.2 Although many reasons could contribute to the lack
of consistent therapeutic efficacy, early ischemia is the lead-
ing cause of transplanted cell apoptosis in host tissue. Early
ischemia can readily induce graft cell death, which markedly
reduces the number of surviving donor cells.3 It therefore be-
comes a technical challenge to find ways to prolong the sur-
vival of the transplanted stem cells.
Among several techniques reported, engineered heart tissue
to replace damaged myocardium has been constructed. Scien-
tists have found that cell-loaded scaffold was more effective at
reducing the infarction area than results seen in those with reg-
ular cell transplantation because the 3-dimensional scaffolds
could provide biomechanical support for the transplanted
cells.4 However, the polymeric fibers cannot provide a vascu-
larized environment to nourish the cells carried, and cell
survival was still poor.5 Historically, omentopexy was used
to provide revascularization for the patient with ischemic heart
disease.6 However, further studies have shown thatgery c December 2010
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dium.7 In recent years, omentopexy combined with basic
fibroblast growth factor or bone marrow mononucleic cells
has been used to promote angiogenesis in the infarcted
myocardium.8,9 However, none of these studies focused on
improving the survival of the engrafted stem cells and were
not shown to ameliorate the undesirable ventricular
remodeling process.
In the current study we developed a new hybrid approach
by including omentum, MSCs, and biodegradable scaffold.
We hypothesized that omentum can improve the microenvi-
ronment of the cell-seeded patch by providing blood supply
and that the improved microenvironment would ensure
greater cell survival. To test the hypothesis, an MI model
was established in female rats, and an omentum-wrapped
polylactic acid-co-glycolic acid (PLGA) patch seeded with
male rat MSCs was grafted onto the epicardium of the infarc-
tion area. The survival and apoptosis of the transplanted
cells, the density of the microvessels, ventricular remodel-
ing, and cardiac function were evaluated. We found that
this process provided a favorable growth environment for
survival of the transplanted MSCs and demonstrated benefi-
cial effects on ventricular remodeling and cardiac function.MATERIALS AND METHODS
Animals
The animal investigation conforms to the ‘‘Guide for the care and use of
laboratory animals’’ published by the US National Institutes of Health (pub-
lication no. 85-23, revised 1996). Sprague–Dawley rats were obtained from
Beijing WTLH Experimental Animal Corporation (Beijing, China; certifi-
cate no. SCXK2004-2005 [Beijing]). All animal experimental procedures
were approved by the Institutional Animal Care and Use Committee, Fu
Wai hospital, and the Beijing Council on Animal Care, Beijing, China.The Journal of Thoracic and CarPLGA Scaffold
PLGA copolymer scaffold was obtained from Professor Ping Hu, De-
partment of Chemical Engineering, Tsinghua University, Beijing, China.
It was manufactured based on an electrospinning technique, as described
previously.10 (The details of the PLGA copolymer are presented in the Ma-
terials and Methods section of this article’s Online Repository.) The copol-
ymer scaffolds were cut into 10-mm-diameter pieces for cell seeding and
implantation as a cardiac patch.
Creation of the Rat MI Model and Grouping
Experiments were performed in 8-week-old female Sprague–Dawley
rats with an initial body weight of 280 to 300 g. The detailed procedure
for creating the rat MI model has been described previously11 (see also
this article’s Materials and Methods section in the Online Repository). Eight
weeks after MI, the cardiac function of the surviving rats was evaluated by
means of echocardiographic analysis (GE Vivid 7; GE, Fairfield, Conn) to
confirm MI status. Those with infarction areas of greater than 25% of the
left ventricular free wall and a left ventricular fractional shortening
(LVFS) of less than 0.25 were selected for the following experiments.
MSC Isolation, Culture, and Seeding on PLGA
Scaffold
MSCs were isolated and harvested on the basis of their preferential ad-
herence to the plastic surface of cell-culture flasks, and the phenotypes
were analyzed on the basis of the positive expression of CD29 and CD44
but negative for CD34 and CD45, as previously described in our labora-
tory.12 MSCs at the second or third passages were used for the experiments.
The morphologic appearance showed that the MSCs had normal prolifera-
tive capability and no evidence for chromosomal abnormalities at the time
of transplantation. After labeling with 40-6-diamidino-2-phenylindole dihy-
drochloride (DAPI; Sigma–Aldrich, St Louis, Mo),13 the MSCs were in-
jected into the PLGA scaffold in 0.5-mL cell suspension (4.0 3 106 cells/
ml), and the MSC–PLGA patches were then incubated in a humidified
5% CO2 atmosphere at 37
C for 3 days until use.
Implantation of MSC–PLGA Patches and Omentum
Wrapping
All rats were anesthetized with ketamine before the hearts were exposed
through the fifth left intercostal space. The infarction area was identified vi-
sually on the basis of surface scarring and abnormal wall motion. For group
P, MSC–PLGA grafts were implanted onto the epicardium of infarcted
myocardium with interrupted sutures. For group O, the omentum was ex-
posed by means of an upper middle laparotomy before an omental flap (ap-
proximately 13 1 cm2) was made carefully to protect its artery and vein as
blood supply. The pedicled omental flap was passed through the diaphragm
into the pericardial space and then covered the infarction area and sutured.
For group PþO, the MSC–PLGA patch was implanted first, and the same
surgical omentopexy process was conducted to cover the patch. After the
operation, the thoracic and abdominal incisions were closed, and animals
were allowed to recover in their cages.
Rats of group P were killed at 1 (n ¼ 4), 2 (n ¼ 3), and 4 (n ¼ 7) weeks,
respectively, after MSC–patch implantation. Rats of group O were killed at 1
(n¼ 5), 2 (n¼ 4), and 4 (n¼ 9) weeks, respectively, after omentopexy. Rats of
group OþP were killed at 1 (n ¼ 3), 2 (n ¼ 3), and 4 (n ¼ 10) weeks, respec-
tively, after MSC–PLGA patch transplantation with omentopexy. Rats of
group MI were killed at 1 (n¼ 7), 2 (n¼ 6), and 4 (n¼ 9) weeks, respectively.
Echocardiographic Assessment of Cardiac Function
Transthoracic echocardiographic analysis was performed on all animals
before and 4 weeks after implantation. A standard protocol was used by 2 dif-
ferent echocardiography physicians during the study.14 Each echocardiogra-
phy physician was blinded to the treatment. Details are presented in the
Materials and Methods section of this article’s Online Repository.diovascular Surgery c Volume 140, Number 6 1389
FIGURE 1. Angiogenesis assessed based on microvessel density and vascular endothelial growth factor (VEGF) protein evaluated by means of Western
blotting. The microvessels in the myocardium were characterized with immunohistochemistry by using anti–von Willebrand factor antibody. The scarred
myocardium in rats with myocardial infarction (MI) was excised at 1 (A, D, and G), 2 (B, E, and H), and 4 (C, F, and I) weeks after polylactic
Evolving Technology/Basic Science Zhou et al
1390 The Journal of Thoracic and Cardiovascular Surgery c December 2010
E
T
/B
S
Zhou et al Evolving Technology/Basic Science
E
T
/B
SHistology and Immunohistochemistry
We fixed hearts in 10% phosphate-buffered formalin, and subjected them
to hematoxylin and eosin, picrosirius red,15 or immunohistochemical analy-
sis. A rabbit polyclonal anti-human von Willebrand factor (Dako, Glostrup,
Denmark) was used as the primary antibody to label endothelial cells (see the
Materials and Methods section of this article’s Online Repository).
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction (PCR) was carried out
to determine the presence of male donor cells with the Y chromosome (Sry
gene) in female recipient hearts, as previously described16 (see also the Ma-
terials and Methods section of this article’s Online Repository).
TUNEL Assay
We performed the terminal deoxynucleotidyl transferase–mediated de-
oxyuridine triphosphate nick end labeling (TUNEL) assay to determine
whether apoptosis happened to the transplanted cells (see the Materials
and Methods section of this article’s Online Repository).
Western Blotting
Western blot analysis was performed to determine the levels of rat myo-
cardial vascular endothelial growth factor (VEGF), stem cell factor (SCF),
and connexin 43 (Cx43; see also the Materials and Methods section of this
article’s Online Repository).
Statistical Analysis
All quantitative variables are expressed as means  standard deviations,
which represent all animals from each experimental group or conditions.
The comparisons of outcomes were made after adjustment for multiple com-
parison analysis. Comparisons among 3 or more groups were performed by
using analysis of variance. Comparisons between 2 groups were performed
by using an unpaired Student t test. Statistical analyses were performed with
SPSS 13.0 software (SPSS, Inc, Chicago, Ill).
RESULTS
Overall, 205 rats were used in the study, including 10 in
the sham group that only received open and closed chest pro-
cedures without any other procedures. Seventy (35.9%) rats
were enrolled and randomly allocated as follows: MI with-
out any treatment (group MI, n ¼ 22), MSC–PLGA patch
implanted (group P, n ¼ 14), omentopexy alone (group O,
n ¼ 18), and MSC–PLGA patch with omentopexy (group
OþP, n ¼ 16). After 4 weeks, the survival rates were 41%,
50%, 50%, and 69%, respectively. The gross characteris-
tics of the experimental rats and PLGA scaffolds were sub-
mitted as shown in Figure E1.
Angiogenesis in the Treated Myocardium
Angiogenesis was demonstrated by the density of micro-
vessels and the level of VEGF, which indicate the activity of
the angiogenenic process. Microvessels were identified ac-
cording to their shapes and positive von Willebrand factoracid-co-glycolic acid–mesenchymal stem cell (PLGA–MSC) transplantation (A,
based PLGA–MSC-supporting patch transplantation (G, H, and I). J, Microvess
millimeter (scale bar ¼ 50 mm [original magnification 403]). Although increased
or PLGA–MSCs compared with that seen in the control group, the VEGF expres
supporting patch at 4 weeks after transplantation (K and L). DP< .05 versus gr
:
The Journal of Thoracic and Carstaining in the infarction scar area. The amount of microves-
sels was obtained in 3 sections, with 4 fields in each section.
As shown in Figure 1, microvessel density was significantly
higher in group PþO than in group O or group P at 1 week
(105.6  14.4 vs 37.3  4.9 vs 41.6  5.9, respectively;
P < .05), at 2 weeks (168.3  17.2 vs 80.1  9.9 vs
76.2  8.6, respectively; P < .05), and at 4 weeks
(225.6  24.6 vs 122.5  14.1 vs 109.0  12.3, respec-
tively; P< .05) after implantation.
Western blotting showed that the highest VEGF level was
0.28 0.03 from group OþP. It was significantly higher than
those from group P (0.23  0.02, P< .05) and group O
(0.22  0.02, P< .05), which in turn was significantly
higher than that from group MI (0.18  0.02, P< .05). As
shown in Figure 1, H, the lowest level was from the sham-
operated group (0.12  0.01) at 4 weeks after implantation.
Apoptosis and Survival of Transplanted MSCs
A TUNEL assay was performed to evaluate the status of
apoptosis in the transplanted MSCs within the infarcted
myocardium. As shown in Figure 2, G, the apoptosis of
MSCs in group OþP was significantly lower than that in
group P at 1 week after implantation (0.07%  0.01% vs
0.12%  0.02%, P< .05). However, apoptosis of MSCs
was reduced in both groups at 2 weeks (0.04%  0.01%
vs 0.06%  0.01%, P > .05) and 4 weeks (0.01% 
0.00% vs 0.02%  0.00%, P> .05) after implantation.
The survival of the implanted MSCs was assessed by de-
tecting the male donor-specific Sry gene in the female recip-
ients, as well as its correlation with the percentage of the
delivered cells that were still present at the various time
points. The specific DNA band for the Sry gene was clearly
visible from the 2 groups that received MSC transplantation
(Figure 3, A). The quantitative real-time PCR showed that
Sry levels decreased over the implantation time in both
groups (Figure 3, C). However, the Sry level from group
OþP was significantly higher than that from group P at 1
week (14.09  1.26 vs 3.81  0.04, P< .05), 2 weeks
(3.34  0.04 vs 1.76  0.02, P < .05), and 4 weeks
(2.61  0.03 vs 1.19  0.02, P<.05) after implantation, re-
spectively. Also, the level of Sry gene signal was closely cor-
related with the delivered cells that were still present in the
infarction area (r2 ¼ 0.99, see Figure E2).
The survival of the implanted MSCs was also evaluated
based on the level of SCF, which was secreted by stem cells.
Western blotting revealed that expression of SCF was the
lowest in the sham-operated rats (0.05  0.01) but the high-
est in rats from group OþP (0.18  0.02), which was alsoB, and C) or transplantation of omentum alone (D, E, and F) or omentum-
el density was quantified as the numbers in blood vessel lumen per square
expression of VEGF was observed in rats with MI who received omentum
sion was the highest in rats that received the omentum-based PLGA–MSC-
oup P, *P< .05 versus group O, and #P< .05 versus the control group.
diovascular Surgery c Volume 140, Number 6 1391
FIGURE 2. Quantification of transplanted MSC apoptosis by means of terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end
labeling the (TUNEL) assay. TUNEL-positive cells were shown as green; the transplanted cells were shown as blue (DAPI). Merged images show that there
were significantly less TUNEL-positive cells in rats with MI that received omentum-based polylactic acid-co-glycolic acid–mesenchymal stem cell (PLGA–
MSC)–supporting patches compared with the PLGAþMSC group at 1 week after transplantation. At 2 or 4 weeks after transplantation, TUNEL-positive cells
were comparable between the 2 groups. Tissue samples of the hearts were excised at 1 (A and B), 2 (C and D), and 4 (E and F) weeks after PLGA–MSC
transplantation (A, C, and E) or omentum-based PLGA–MSC-supporting patch transplantation (B, D, and F). Scale bar ¼ 20 mm (original magnification
403) G, The percentage of apoptotic MSC nuclei both in group OþP and group; quantitative estimations of TUNEL-positive cells in each group are shown
in the bar chart. DP< .05 versus group P.
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FIGURE 3. Quantifying transplanted male mesenchymal stem cells (MSCs)
in the female ischemic myocardium. A, Sry is expressed only in male rat cells.
The polymerase chain reaction (PCR) product size is 213 bp. B, Dissociation
curve of the real-time PCR. C, Time course of transplanted MSC survival. The
survival of MSCs decreased from 1 to 4 weeks after transplantation in both
groups. Viable MSCs were significantly higher in rats that received
omentum-based polylactic acid-co-glycolic acid (PLGA)–MSC-supporting
patch at each time point. DP< .05 versus group P.
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This was in turn higher than those of group O and group MI
(0.09  0.01 and 0.07  0.01, respectively; both P< .05) 4
weeks after implantation (Figure 4, N).
Ventricular Remodeling
Ventricular remodeling was illustrated by the changes in
left ventricular end-diastolic diameter (LVEDD) and left
ventricular end-systolic diameter (LVESD) in echocardio-
graphic analysis and the distribution of the collagen density.
The concentration of connective protein (Cx43) was deter-
mined to evaluate the level of transplanted cells structurally
coupled with the host myocardium.The Journal of Thoracic and CarAs shown in Table 1, 4 weeks after implantation, both
LVEDD and LVESD were lower in group OþP (LVEDD,
8.18  1.69 mm; LVESD, 6.06  1.73 mm) than in group
P (LVEDD, 9.45  1.75 mm; LVESD, 6.89  1.58 mm),
group O (LVEDD, 9.56  1.93 mm; LVESD, 6.96  1.83
mm), and group MI (LVEDD, 9.73  1.26 mm; LVESD,
6.92  1.43 mm). The differences between group OþP and
all other groups were statistically significant, respectively
(P< .05). Picrosirius red staining under polarized micros-
copy demonstrated that collagen density in the infarction
zone from the 4 groups was 47%  6% (group MI),
39%  4% (group O), 26%  3% (group P), and
16%  2% (group OþP), respectively, 4 weeks after im-
plantation. There were significant differences between any
pair of the 4 groups (Figure 4, E–L). The omentum-
wrapped patch resulted in more significant collagen reduc-
tion than treatment with the MSC–PLGA patch or omentum
alone. The highest level of Cx43 was in the sham-operated
group (0.31 0.03). Four weeks after implantation, the low-
est level appeared in group MI, which did not receive any
treatment (0.11  0.01). There were no significant differ-
ences between group MI and group O (0.14 0.02) or group
P (0.19  0.02). However, the Cx43 level in group OþP
(0.23 0.03) was significantly higher than those in the other
3 groups (P< .05 with all 3 group; Figure 4, P and Q).
Cardiac Functional Evaluation
Left ventricular pump function was evaluated by means of
echocardiographic analysis. The left ventricular ejection
fraction (LVEF) and LVFS were reduced by means of
LAD ligation to a baseline level (Table 1). There were not
any differences in cardiac function among different groups
before implantation. Four weeks later, LVEF and LVFS
were increased significantly more in group OþP (LVEF,
59.2%  5.07%; LVFS, 22.8%  2.5%) than in group P
(LVEF, 52.2%  4.33%; LVFS, 20.6%  3.4%) or group
O (LVEF, 51.9%  5.06%; LVFS, 20.3%  2.3%). Car-
diac function was improved only in group OþP.
DISCUSSION
The therapeutic potential of stem cells for cardiac repair is
potentially revolutionary. However, survival of the grafted
cells has hampered long-term therapeutic effects.16 In this
study we successfully established a technique for cell trans-
plantation with an omentum-based supporting patch in an
experimental rat model. The main findings of this study
are as follows. First, omentum wrapping enhanced survival
of MSCs seeded in the PLGA scaffold by reducing early ap-
optosis of the cells. Second, the omentum-wrapped MSC–
PLGA patch enhanced angiogenesis in the infarction area.
Third, the omentum-wrapped MSC–PLGA patch improved
the ventricular remodeling process 4 weeks after implanta-
tion. Fourth, the omentum-wrapped MSC–PLGA patch ap-
peared to restore cardiac function more effectively. Morediovascular Surgery c Volume 140, Number 6 1393
FIGURE 4. Evaluation of ventricular remodeling and expression of stem cell factor (SCF) and connexin 43 (Cx43) after transplantation. A to H, Picrosirius red
staining. I to L, Observed under polarized light. A to D, Gross view of the hearts. E to L, Sections from peri-infarction zone. The samples were excised 4 weeks
after transplantation from rats with myocardial infarction (MI) that received no treatment (A, E, and I), rats with MI that received only omentum (B, F, and J), rats
with MI treated with polylactic acid-co-glycolic acid–mesenchymal stem cells (PLGA–MSCs; C, G, and K), and rats with MI that received the omentum-based
PLGA–MSC-supporting patch (D, H, and L). Collagen volume in the ventricle was reduced in rats treated with PLGA–MSCs than in the rats with MI that received
no treatment. Rats with MI that received the omentum-based PLGA–MSC-supporting patch demonstrated further reduction in the collagen. M, The percentage of
collagen content. Western blotting demonstrated that SCF expression was upregulated in rats that received MSCs compared with control rats or rats with MI that
received either no treatment or omentum only (N and O). Western blotting demonstrated that there was a marked increase in Cx43 expression in the host myo-
cardium after omentum-based PLGA–MSC-supporting patch transplantation compared with that seen in all other groups of rats (P and Q). Scale bar ¼ 20 mm
(original magnification 403). DP< .05 versus group P, *P< .05 versus group O;:P< .05 versus group MI, and #P< .05 versus the control group.
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omentum-based MSC–PLGA patch created a vascularized
microenvironment that prolonged the survival of trans-
planted stem cells and improved cardiac performance.TABLE 1. Serial echocardiographic analysis
Time point
and pa rameter Group MI Group
Baseline
LVEDD (mm) 6.76  0.42 6.96  0
LVESD (mm) 5.31  0.37 5.26  0
LVFS (%) 24.5  4.1 24.3  3
LVEF (%) 62.3  5.62 61.1  5
4 wk
LVEDD (mm) 9.73  1.26 9.56  1
LVESD (mm) 6.92  1.43 6.96  1
LVFS (%) 20.2  1.8 20.3  2
LVEF (%) 51.6  5.26 51.9  5
MI, Myocardial infarction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ven
ventricular ejection fraction. *P< .05 versus group MI. yP< .05 versus group P. zP< .05
1394 The Journal of Thoracic and Cardiovascular SurCardiomyocyte death is inevitable after MI. Unlike endo-
thelial cells, cardiomyocytes can hardly be regenerated in
adults. Current CABG or percutaneous coronary interven-
tion therapy might establish the revascularization of theO Group P Group OþP
.63 6.91  0.45 7.02  0.49
.39 5.29  0.41 5.35  0.43
.9 23.9  2.6 23.7  3.2
.66 64.7  5.95 63.9  4.25
.93 9.45  1.75 8.18  1.69*,y,z
.83 6.89  1.58 6.06  1.73*,y,z
.3 20.6  3.4 22.8 2.5*,y,z
.06 52.2  4.33 59.2  5.07*,y,z
tricular end-systolic diameter; LVFS, left ventricular fractional shortening; LVEF, left
versus group O.
gery c December 2010
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cytes during the infarction, which ultimately leads to fibrotic
ventricular remodeling and heart failure. Therefore replen-
ishing the post-MI heart with fresh cells by means of external
supply appears to be feasible in restoration of viable myocar-
dium. Findings that MSCs are able to transdifferentiate to
functional mature cardiomyocytes have raised the hope for
cell-based therapy to repair damaged myocardium.17 How-
ever, recent studies failed to generate reproducible benefits
for the impaired heart.18 Although many factors could con-
tribute to the inconsistent efficacy, poor viability of the
grafted MSCs might play a major role.
Multiple adverse factors, including transplant tissue is-
chemia, and host-related factors, including inflammatory
and immune responses, could contribute to the poor viabil-
ity. However, MSCs have been commonly regarded as
low immune response–invoking cells because of their undif-
ferentiated characters. Studies from other groups have
proved the safety of allogeneic MSC transplantation.19 Sim-
ilarly, in our study we also did not find obvious immune re-
jection after MSC transplantation in group P and group OþP.
Therefore it seems that early ischemia is the leading cause of
the loss of transplanted cells.16 Mu¨ller-Ehmsen and col-
leagues20 reported that the survival of transplanted MSCs
was only 27%, 4%, and 1% 2, 5, and 21 days after intra-
myocardial injection, respectively. In attempting to conquer
this problem, Retuerto and associates21 transferred the
VEGF gene into neonatal myocardial cells and injected
them into ischemic myocardium. Although the number of
surviving cells increased, the retained cells were only 330
in 1550 (cell number per field of 4003) within 5 weeks. Ad-
ditionally, seeding cells on scaffolds to construct several
types of cell patches to repair infarcted myocardium has
been tested. Despite the promise of scaffold technology,
the survival of transplanted cells was still poor. Jin and co-
workers4 reported that the infarction area was decreased
and levels of cardiac markers (major histocompatibility
complex and troponin-I) were increased in the MSC scaffold
group compared with those seen in the MSC group. Simpson
and colleagues5 transplanted MSC–collagen cell patches
into infarcted myocardium, but MSCs were not detectable
4 weeks later.
The omentum once played an active part in surgical revas-
cularization for ischemic heart disease. In 1965, Vineberg
and associates22 reported a cardio-omentopexy procedure.
However, it became obsolete after development of CABG
or percutaneous transluminal coronary angioplasty because
omentopexy with or without internal thoracic artery implan-
tation did not result in sufficient revascularization. Recently,
Takaba and coworkers8 transplanted a gelatin hydrogel sheet
incorporating 100 mg of basic fibroblast growth factor with
omentopexy, and Kanamori and colleagues9 transplanted
MSCs with omentopexy. Both studies showed that the com-
bination therapy was more effective than isolated transplan-The Journal of Thoracic and Cartation of MSCs or transplantation with scaffold. However,
these studies only investigated angiogenesis. They did not
study the survival of the engrafted stem cells and did not
prove to ameliorate ventricular remodeling process. In our
experiment we established an omentum-based MSC–
PLGA patch that uses the advantages of both angiogenesis
and biodegradable scaffold. Indeed, our data showed much
more microvessel growth in the myocardium of the rats
with MI that received omentum-based MSC–PLGA patches
than seen with those with the omentum or cell patch alone.
In this experiment we did not see significant evidence of
collateral between coronary and omentum arteries. Because
the nutrition and oxygen exchange of infarction area largely
depend on capillaries from either omentum or the adjacent
peri-infarction zone, the enhanced angiogenesis might con-
tribute to the perfusion of the infarction area. Although
more studies are needed, our findings suggest that
omentum-stimulated neovascularization is superior. First,
the abundant omentum microvessels are likely to grow
into the cell patch and improve outer and middle layer myo-
cardium blood supply. Second, microvessels of the host
heart might grow into the infarction area. Third, the para-
crine effect of MSCs, such as increased VEGF expression,
in the omentum-based MSC–PLGA patch will further pro-
mote angiogenesis.
Our data demonstrated survival benefits in the trans-
planted MSCs when the omentum-based PLGA–MSC-sup-
porting patch was used. Several mechanisms might explain
the findings. Obviously the increased microvessels would
provide a better blood supply. In addition, because omentum
is rich in lymphatic circulation, factors detrimental to the
survival of transplanted MSCs can be promptly removed
through the lymph circulation. The omentum also has a large
number of macrophages, which can clean up dead cells and
minimize the associated inflammatory process. Omentum
can secrete several cytokines, which is important for MSC
proliferation and differentiation.23 In addition to the favor-
able microenvironment provided by the omentum, omentum
can be a rich stem cell source by itself.24
Our experimental rats showed a favorable cardiac remod-
eling process in the left ventricle near the infarction area in
rats that received omentum-based MSC–PLGA patches.
LVFS in group P had no significant preservative effects
compared with those in group MI, as shown in our echocar-
diographic data. This result is similar to the study of van der
Bogt and colleagues,25 which suggested a limited benefit of
MSC transplantation because of the loss of MSCs. It is pos-
sible that the PLGA scaffold on epicardium might absorb
regional ventricular wall stress to prevent infarcted myocar-
dium from expanding before PLGA degraded. Four weeks
after transplantation, we found PLGA degradation was
more apparent in group OþP compared with that seen in
group P (see Figure E3). With PLGA fiber degradation,
the transplanted cell patch fused with the native myocardiumdiovascular Surgery c Volume 140, Number 6 1395
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Sand thickened the infarcted wall. According to the law of
Laplace, ventricular wall stress decreased when ventricular
wall becomes thicker. The increased SCF released from
MSCs in the omentum-based MSC–PLGA patch could fur-
ther contribute to this favorable ventricular remodeling pro-
cess. Paracrine cytokines from MSCs are one of the
beneficial mechanisms of cell transplantation, although
MSC-structured coupling with native cardiomyocytes might
result in further improvement. Cx43 is a gap junction protein
that is responsible for connections and electrical coupling
between cardiomyocytes and closely aligned cells. Previous
studies suggest that global upregulation of Cx43 in the host
myocardium is important for the restoration of cardiac func-
tion.26 In our study we found that the enhanced level of Cx43
was in accordance with the improvement of cardiac function
in rats with MI, and the rats receiving omentum-based
MSC–PLGA patch treatment showed improved cardiac
function compared with that seen in group O and group P.
In summary, we established a novel model for the
omentum-based MSC–PLGA patch that can prolong MSC
survival after transplantation, modify ventricular remodel-
ing, and restore cardiac function in rats with experimental
MI. The combined use of omentopexy and PLGA scaffold
creates a favorable microenvironment for the survival of
transplanted MSCs and modifies ventricular remodeling.
Our omentum-based MSC–PLGA model, once validated
in human subjects, would be a valuable tool in stem cell ther-
apy for the failing heart.
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MATERIALS AND METHODS
PLGA Copolymer
The ratio of lactic acid and glycolic acid was 50:50, with a final copolymer
molecular weight of 100 kd. The pore diameter and porosity of the
scaffold were 160 to 170 mm and 85%, respectively. The thickness was
600 to 700 mm.
Creation of the Rat MI Model
Briefly, rats were tracheally intubated with 2% to 3% isoflurane in ox-
ygen by using a Harvard ventilator (model 683; Harvard Apparatus, Hollis-
ton, Mass). The rat heart was exposed, and MI was created by means of
ligation of the LAD 2 to 3 mm from the tip of the left auricle. Successful
performance of coronary occlusion is verified by observation of the devel-
opment of pale color in the distal myocardium.
Protocol for 2-Dimensional Echocardiographic
Methodology
Transthoracic echocardiographic analysis was performed on all animals
before and 4 weeks after omentum, MSC patch, or omentum-based MSC
patch transplantation. A standard protocol was used by 2 different echocar-
diography physicians during the study. Briefly, after achievement of general
anesthesia, animals were placed in the left lateral decubitus position, and
transthoracic 2-dimensional echocardiographic analysis was performed
with the Vivid 7 (GE) ultrasound system and a 10-MHz multiphase array
probe. Measurements were made in 3 cycles, and the mean value was ob-
tained. LVEDD and LVESD were derived from 2-dimensionally targeted
M-mode tracings obtained along the parasternal short-axis view of the
left ventricle at the papillary muscle level, according to the methods of
the American Society of Echocardiology. LVFS as a measure of systolic
function was calculated as follows: LVFS (%) ¼ [(LVEDD LVESD)/
LVEDD]/100. Each echocardiography physician was blinded to the
treatment.
Histology and Immunohistochemistry
After death, hearts were excised, and the treated area was examined mac-
roscopically. Then a horizontal round strip was cut between the upper and
lower edges of the treated area. Each specimen was cut into 3 parts. A whole
strip containing the left ventricle, interventricular septum, and right ventri-
cle was fixed in 10% phosphate-buffered formalin, embedded in paraffin,
and sectioned in 10-mm-thick slices. The second part from the center of
the treated area was frozen in liquid nitrogen for Cryostat sectioning (5
mm in thickness). The third part, obtained from the remained treated area,
was mixed and homogenated for RT-PCR and Western blotting.
Paraffin sections were stained with hematoxylin and eosin, picrosirius
red, or immunohistochemical reagents, respectively. A picrosirius polariza-
tion method was used to determine semiquantitative collagen levels. The
differently stained sections were observed under a light microscope, and
digital images were captured for collagen determination (BX61 microscope,
DP-70 digital camera, DP Manager software; Olympus, Tokyo, Japan). The
collagen density was defined as collagen area/total tissue area in the same
visualized fields.
Three continuous sections from each rat were prepared for immunohis-
tochemical testing. A rabbit polyclonal anti-human von Willebrand factor
(Dako) was used as the primary antibody. All antibody–antigen complexes
were visualized with the ABC staining system (Santa Cruz Biotechnology,
Santa Cruz, Calif). Microvessels were identified according to their shapes
and positive von Willebrand factor staining and counted in 4 randomly se-
lected fields in each section under magnification of 2003 with microscopy
(BX61, Olympus). The microvessel density was expressed as the microves-
sel number per square millimeter, as described previously.
Quantitative Real-Time PCR
Samples from group P and group OþP, which involved cell transplanta-
tion, at 1, 2, and 4 weeks after implantation were used for quantitative real-
time PCR analysis to determine the presence of male donor cells with the Y
chromosome (Sry gene) in female recipient hearts.
Genomic DNA for the PCR template was extracted from the above ho-
mogenate according to the method provided by the Wizard Genomic
DNA Purification Kit (Promega, Madison, Wis). A specific primer for the
rat Sry gene was designed: sense, 5- ATC GAA GGG TTA AAG TGC -
3; antisense, 5- GTT TCT GCT GTA GTG GGT AT -3. The quantitative
real-time PCR was carried out on an ABI Prism 7700 Sequence Detection
System (ABI, Foster City, Calif). Genomic DNA templates (100 ng) were
used in PCR reactions (50 mL) with rat primers and commercial reagents
from Power SYBR Green PCR Master Mix Kit (Applied Biosystems, War-
rington, United Kingdom), according to the instructed protocol. The final
product (213 bp) was separated on a 2% agarose gel and photographed
with ultraviolet light. The Sry gene level was expressed as the ratio of optical
density from each sample to the density from the reference at the same time.
TUNEL Assay
The TUNEL assay was performed to determine whether apoptosis oc-
curred in transplanted cells. Cryostat sections from group P and group
OþP, which involved cell transplantation, at 1, 2, and 4 weeks after implan-
tation were used for the assay with Fluorescein FragEL DNA Fragmentation
Detection Kit (Calbiochem, Darmstadt, Germany), according to the manu-
facturer’s instructions. Three continuous sections were examined for each
rat. In each section 4 visual fields with a magnification of 403 were ran-
domly selected for counting. Total transplanted MSCs were labeled with
DAPI in blue, and TUNEL-positive cells were stained in green. Merged im-
ages with double-positive nuclei were identified as transplanted MSCs un-
dergoing apoptosis with fluorescence microscopy (Olympus BX61, Japan).
The apoptotic index was calculated as the ratio of apoptotic cells to total
cells expressed as a percentage.
Western Blotting
Western blot analysis was performed to determine the levels of rat myo-
cardial VEGF, SCF, and Cx43. Protein samples (30 mg of protein) from all
groups after 4 weeks of implantation, extracted from the above homogenate,
were mixed with an equal volume of sample buffer and boiled for 15 min-
utes before loading onto 10% polyacrylamide gels. The electrophoresed
proteins were transferred from the gel to the nitrocellulose membranes
(Bio-Rad Laboratories, Hercules, Calif). The membranes were incubated
for 60 minutes with 5% dry milk and Tris-buffered saline to block nonspe-
cific binding sites. Membranes were immunoblotted overnight at 4C with
anti-Cx43 (1:500; Chemicon International, Temecula, Calif), anti-VEGF (1
in 400, Santa Cruz Biotechnology), anti-SCF (1:500, Santa Cruz Biotech-
nology), or anti–b-actin (1:250, Dako Cytomation) antibodies. After 33
5-minute washings, the membranes were incubated for an hour with horse-
radish peroxidase–conjugated secondary antibody. This was followed by
washing and developing with the ECL plus kit (Bio-Rad Laboratories).
VEGF, SCF, and Cx43 levels were expressed as a ratio to the level of
b-actin, which was run on all blots.
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FIGURE E1. Macroscopic characteristics of the rats with MI and PLGA scaffold. A, Photomicrographs of the PLGA patch. The PLGA patch was a dense
layer with uniform pores. B, The punched 1-cm diameter PLGA patch is the size used to carry the MSCs for transplantation. C, Myocardial infarction was
generated by means of LAD ligation. Eight weeks after ligation, the infarcted myocardium showed as a pale color, as indicated by the red arrow. D, Four
weeks after transplantation, the macroscopic view of the animal revealed that the omentum supporting the cell patch was tightly connected with the host heart.
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FIGURE E2. Correlation between Sry gene signal and DAPI cell number.
DAPI-positive cells were counted under fluorescence microscopy (original
magnification 2003) in group P and group OþP before MSC patch transplan-
tation and 1, 2, and 4 weeks after transplantation, respectively. Sry gene sig-
nal was evaluated at the same time points. The correlation of DAPI-positive
cell numbers and Sry gene signal was analyzed and shown in Figure E2. The
results showed that Sry gene signal was closely correlated with the delivered
cells that were still present in the infarction area (r2 ¼ .99).
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FIGURE E3. The histologic change of the PLGA polymer after transplantation: PLGA degradation in vivo. There is no obvious difference in PLGA fibers
between the MSC–PLGA patch transplantation group (A) and the omentum-wrapped MSC–PLGA patch group (B) 1 week after transplantation. However, 4
weeks after transplantation, the remnants of PLGA in the omentum-wrapped MSC–PLGA patch group (D) were less than that in the MSC–PLGA patch group
(C; PLGA fibers are indicated by a yellow arrow).
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